Flash e-reader

 Go to e-reader chapter








Table 11.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1999 to 2008

Recipients with Heart Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 2,188 2,199 2,202 2,155 2,057 2,015 2,125 2,193 2,209 2,163
Tx with Antirejection Treatments 916 902 849 803 656 533 533 485 430 382
Antibodies Any in Category 17.7% 16.4% 15.5% 17.4% 18.4% 15.6% 18.0% 19.2% 17.0% 19.9%
Atgam/NRATG/NRATS 6.3% 4.7% 3.9% 4.0% 4.6% 2.6% 2.4% 3.5% 5.1% 5.0%
OKT3 7.4% 5.1% 5.8% 6.8% 4.1% 3.2% 3.4% 3.7% 1.4% 2.9%
Thymoglobulin 2.0% 3.8% 4.9% 6.4% 7.5% 8.6% 9.4% 11.1% 9.3% 11.5%
Zenapax 2.5% 3.0% 2.5% 1.5% 2.0% 1.5% 3.6% 1.6% 2.6% 2.6%
Simulect 0.9% 2.0% 0.4% 0.4% 1.4% 0.6% 0.8% 0.2% 0.2% 0.0%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.2% 0.2% 0.2% 0.0% 0.3%
Corticosteroids Any in Category 91.3% 92.4% 92.7% 92.2% 92.5% 91.4% 90.8% 90.5% 89.5% 90.3%
Steroids 91.3% 92.4% 92.7% 92.2% 92.5% 91.4% 90.8% 90.5% 89.5% 90.3%
Antimetabolites Any in Category 4.6% 4.4% 2.0% 3.0% 3.5% 1.7% 2.3% 1.9% 2.3% 1.8%
Cytoxan 2.1% 1.7% 0.5% 0.9% 1.7% 1.3% 1.3% 1.6% 2.1% 1.3%
Methotrexate 2.6% 2.8% 1.5% 2.1% 1.8% 0.4% 0.9% 0.2% 0.2% 0.5%


Source: OPTN/SRTR Data as of October 1, 2010.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.